DDIT3 and diffuse large B-cell lymphoma: The phase 2 part of the trial (venetoclax plus R-CHOP) was conducted only in newly diagnosed DLBCL patients and the results were compared to matched historical controls from the GOYA phase 3 trial (R-CHOP treated patients) [27].